Isabel Kalofonos's most recent trade in Crinetics Pharmaceuticals Inc was a trade of 100,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 10, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Crinetics Pharmaceuticals Inc | Isabel Kalofonos | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
Immunogen, Inc. | Isabel Kalofonos | SVP & CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 284,250 | 284,250 | - | - | Stock Option (Right to Buy) | |
Immunogen, Inc. | Isabel Kalofonos | SVP & CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 47,375 | 47,375 | - | - | Restricted Stock Unit |